Cardiovascular

Lusofarmaco has a long tradition in the cardiovascular field, thanks to many years of interest in cardiological drugs.
The company drug list belongs to several pharmacological classes such as calcium-channel blockers, nitrates, beta-blockers, statins, and a drug for the treatment of arterial hypotension, each represented by molecules of recognized efficacy and consolidated clinical use.
 

Brand name Molecule ATC category Packaging Class
Aloneb Nebivolol + HCTZ Beta-blockers + diuretic 28 tablets 5/12,5 mg A
28 tablets 5/25 mg A
Bifrizide Zofenopril + HCTZ ACE-inhibitors + Diuretics 28 tablets 30 mg / 12,5 mg A
Diuremid Torasemide Diuretic 14 scored tablets 10 mg A
10 mg / 2 ml solutions for injections - 5 vials A
200 mg / 20 ml solutions for injections - 1 vial

H

Gutron Midodrine Adrenergics and dopaminergics 30 tablets 2,5 mg C
drops 30 ml 0,25% C
Monocinque Isosorbide-5-mononitrate Organic nitrates 50 tablets 20 mg A
30 tablets 40 mg A
Retard - 30 capsules 50 mg A
Retard - 30 capsules 80 mg A
Nobistar Nebivolol Beta-blocker 28 tablets 5 mg A
Prasterol Pravastatin sodium HMG-CoA reductase inhibitors 10 tablets 20 mg A13
14 tablets 40 mg A13
Tranex Tranexamic acid Antihaemorrhagics 30 capsules 250 mg A
30 capsules 500 mg A
6 vials 500 mg/5 ml A
 Rosuvastatine
 Rosuvastatine

Our products

Lusofarmaco can claim extensive know-how in various therapeutic areas: cardiovascular and respiratory diseases, antibiotic therapy, neuropsychiatry and gynecology.

Research & Development

For many years, Lusofarmaco has been mainly a national company, with a portfolio focused on well-established medicinal products, which have been the reference drugs in their respective therapeutic areas.

Pharmacovigilance

Pharmacovigilance: what does it mean to monitor drugs?

Registered Office:
Milanofiori – Strada 6, Edificio L – 20089 Rozzano (MI)
Tel. 02-516555.1

Registration No. In Registrar Of Companies: 00714810157
Registrar Of Companies' Office: Milano
Registered Capital: € 130.000 I.V.
Capital Reported In Last Financial Statement: € 130.000
Company subject to the direction and coordination of A. Menarini Industrie Farmaceutiche Riunite Srl

SITEMAP

Copyright 2024 Istituto Lusofarmaco D'Italia S.p.A.